| ||Format||Pages||Price|| |
|6||$45.00||  ADD TO CART|
|Hardcopy (shipping and handling)||6||$45.00||  ADD TO CART|
Significance and Use
4.1 This guide is not intended to specify the exact method of conducting a test for any particular material but only to present some of the criteria that should be considered in method design and possible problems that could lead to misleading results. In the development of the actual test protocol, it is recommended that recognized tumorigenesis bioassay procedures be consulted.
4.2 The recommendations given in this guide may not be appropriate for all applications or types of implant materials. These recommendations should be utilized by experienced testing personnel in conjunction with other pertinent information and the requirements of the specific material application.
1.1 This guide is intended to assist the biomaterials testing laboratory in the conduct and evaluation of tumorigenicity tests to evaluate the potential for new materials to evoke a neoplastic response. The procedure is generally reserved only for those materials which have not previously been used for human implantation for a significant period of time.
1.2 Assessment of tumorigenicity is one of several procedures employed in determining the biological response to a material as recommended in Practice F748. It is assumed that the investigator has already determined that this type of testing is necessary for a particular material before consulting this guide. The recommendations of Practice F748 should be considered before a study is commenced.
1.3 Whenever possible, it is recommended that a battery of genotoxicity procedures be initiated and proposed as an alternative to an in-vivo tumorigenicity bioassay. Genotoxicity assays may also be considered as initial screening procedures due to the sensitivity of the assays, the significant reduction in time to gain valuable data, and the desire to reduce the use of animals for testing. Genotoxicity assays that may be considered are outlined in Guides E1262, E1263, E1280, and E2186, and Practices E1397 and E1398. Additionally, other genotoxicity testing which might be considered (but which do not yet have ASTM test methods) include Salmonella/Mammalian-Microsomal Plate Incorporation Mutagenicity Assay, In Vivo Cytogenetics Bone Marrow Chromosomal Damage Assay, BALB/3T3 Morphological Transformation of Mouse Embryo Cells, and the Mouse Micronucleus Assay. The investigator is advised to consider carefully the appropriateness of a particular method for his application after a review of the published literature.
1.4 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.
2. Referenced Documents (purchase separately) The documents listed below are referenced within the subject standard but are not provided as part of the standard.
E1262 Guide for Performance of Chinese Hamster Ovary Cell/Hypoxanthine Guanine Phosphoribosyl Transferase Gene Mutation Assay
E1263 Guide for Conduct of Micronucleus Assays in Mammalian Bone Marrow Erythrocytes
E1280 Guide for Performing the Mouse Lymphoma Assay for Mammalian Cell Mutagenicity
E1397 Practice for In Vitro Rat Hepatocyte DNA Repair Assay
E1398 Practice for In Vivo Rat Hepatocyte DNA Repair Assay
E2186 Guide for Determining DNA Single-Strand Damage in Eukaryotic Cells Using the Comet Assay
F748 Practice for Selecting Generic Biological Test Methods for Materials and Devices
Other DocumentsGood Laboratory Practice for Nonclinical Laborator OECD Guidelines for Testing of Chemicals: Guidelin Chronic Toxicity/Carcinogenicity Studies OECD Guidelines for Testing of Chemicals: Guidelin Studies Available from Organization for Economic Cooperation and Development, 2001 L Street, N.W., Suite 650, Washington, D.C. 20036-4922. http://www.oecd.org/washington/contact.htm.
ICS Number Code 11.040.40 (Implants for surgery, prothetics and orthotics)
|Link to Active (This link will always route to the current Active version of the standard.)|
ASTM F1439-03(2013), Standard Guide for Performance of Lifetime Bioassay for the Tumorigenic Potential of Implant Materials, ASTM International, West Conshohocken, PA, 2013, www.astm.orgBack to Top